Clinical Trials and Research

AccurKardia said it was granted a U.S. patent for its machine-learning-based algorithm that can identify cardiac amyloidosis from a standard 12-lead ECG. Use of ECG…

In people with transthyretin amyloid cardiomyopathy (ATTR-CM), the buildup of faulty transthyretin (TTR) protein in the heart may contribute to blood clots that…

At the European Society of Cardiology's Heart Failure Congress in Barcelona, ​​Bayer announced the results of new analyses of acoramidis in transthyretin amyloid…

AbstractBackground: The care of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) is often fragmented and routine datasets rarely capture real-world…

NAPLES, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives…

It has been a busy period for the amyloidosis treatment field. In April, Danish drugmaker Novo Nordisk (NOV: N) received US Food and Drug Administration (FDA) Fast…

AbstractPurposeScintigraphy using 99mTc-labeled bone-seeking tracers is a cornerstone in the non-invasive diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM…

Transthyretin cardiac amyloidosis (ATTR-CM) is an increasingly recognized cause of heart failure and conduction disease in older adults. Resulting from either…

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, often fatal condition driven by misfolded transthyretin (TTR) protein deposits in the heart muscle…

Details and patient eligibilityAboutThis study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in…